Dec 3, 2025
Grand Hi-Lai Hotel Taipei, Platinum Grand Ballroom B, Taipei, Taiwan
Driving Innovation, Investing in the Future
[The forum is co-organized by the RBMP, IBMI, and Everbright Biofund.]
What You’ll Gain:
MedTex is where global investors and startups converge each year. As Asia’s leading gateway to health-tech innovation, it connects capital, innovation, and future opportunities.
Investment Foresight
Stay ahead with exclusive insights from world-leading VCs, and capture the next wave of healthcare investment trends
Global Capital Connections
Forge partnerships with international investors, corporates, and strategic collaborators to unlock global opportunities
Deal Flow Access
Spot the next generation of breakthrough startups backed in healthcare and biotech sectors.
What You Need to Know
This Event is Invitation Only
To ensure the quality of the forum and proper seating arrangements, participation is by invitation only.
NT$ 5,000 / seat (Lunch Included)
The registration fee is NT$5,000 per person. Lunch and refreshments are provided.
Available till November 20
As seats are limited, please complete your registration by November 20 to secure your seat.
If you would like to recommend investors or industry leaders to attend, please contact:
+886-2-2655-7888 Ext.632 (Dr. Shih), Ext.634 (Dr. Chen), Ext.673 (Dr. Wang)
The summit provides real-time AI translation.
Event Agenda
Keynote Speech
Building the Next Frontier: Life Science Investment Strategies for 2026 and Beyond
• Noel Jee | Partner, Novo Holdings
10:10 – 10:40
AI and the transformation of HealthTech – an Investor Perspective
• Yaron Daniely | General Partner, aMOON Fund
10:40 – 11:10
• Noel Jee | Partner, Novo Holdings
• Yaron Daniely | General Partner, aMOON Fund
Pitch Session I
- Iambic Therapeutics ∣ Tom Miller, Co-Founder & CEO
- Manifold Bio ∣ Gleb Kuznetsov, Co-Founder & CEO
- Arrepath ∣ Kevin Krause, President & CEO
- Myria Biosciences ∣ Steven Schmitt, CEO
AI Drug Discovery & Therapeutics
- Tom Miller ∣ Co-Founder & CEO, Iambic Therapeutics
- Gleb Kuznetsov ∣ Co-Founder & CEO, Manifold Bio
- Kevin Krause ∣ President & CEO, Arrepath
- Steven Schmitt ∣ CEO, Myria Biosciences
11:10 – 12:30
Fireside Chat
- Insight Partners ∣ Aiden Aceves, Vice President
- Playground Global ∣ Benjamin Kim, Partner
- Illumina ventures ∣ Charles Lin, Principle
- Ascenta Capital ∣ Leighanne Oh, Vice President
Investing in the Future of Healthcare: Trends and Opportunities in 2026
- Aiden Aceves ∣ Vice President, Insight Partners
- Benjamin Kim ∣ Partner, Playground Global
- Charles Lin ∣ Principle, Illumina ventures
- Leighanne Oh ∣ Vice President, Ascenta Capital
13:30 – 15:00
Pitch Session II
- Nanoflex Robotics ∣ Matt Curran, Co-Founder & CEO
- OpenWater ∣ Aaron Timm, CEO
Medical Robotics & HealthTech Innovation
- Matt Curran ∣ Co-Founder & CEO, Nanoflex Robotics
- Aaron Timm ∣ CEO, OpenWater
15:00 – 15:30
Pitch Session II
- caVos Biotech ∣ Haim Belinson, CEO
- Coltac Therapeutics ∣ Yaron Sfadyah, CEO
- Infinimmune ∣ Wyatt McDonnell, Co-Founder & CEO
- Insamo ∣ Tim Craven, CEO
New Therapeutics & Drug Innovation
- Haim Belinson ∣ CEO, caVos Biotech
- Yaron Sfadyah ∣ CEO, Coltac Therapeutics,
- Wyatt McDonnell ∣ Co-Founder & CEO, Infinimmune
- Tim Craven ∣ CEO, Insamo
15:50 – 17:00
Investor & Innovator Networking
15:50 – 17:00
VCs (Venture Capitalists)
Noel Jee
Partner
Noel Jee is a Partner at Novo Holdings and broadly invests across healthcare and the life sciences. Previously a healthcare investor with Sofinnova Investments and Illumina Ventures, Noel honed his investment experience across therapeutics, life science tools, diagnostics, and healthcare platforms. Prior to his time in venture capital, he was a management consultant at L.E.K. Consulting.
Noel received his PhD in Chemistry and Chemical Biology from the University of California, San Francisco. Noel also holds a dual B.S. in Biochemistry and a B.S. in Neurobiology and Physiology from the University of Maryland, College Park, where he graduated with Honors.
Yaron Daniely
General Partner
Dr. Yaron Daniely is a General Partner at aMoon Fund, where he co-leads Velocity, aMoon’s early-stage investment fund. Prior to aMoon, Yaron was the President and CEO of Yissum, Hebrew University’s Technology Transfer Company, and Co-Chairperson of the Israel Technology Transfer Network. Before leading Yissum, he spent 14 years as a senior executive of private and NASDAQ-traded Biotech companies. Yaron earned his PhD from NYU, served as a Visiting Fellow at the NIH, and as an American Cancer Society Postdoctoral Fellow at The Weizmann Institute for Science in Israel. He also holds an MBA from the Technion.
Aiden Aceves
Vice President
Aiden Aceves is a Vice President on the investments team at Insight. He joined the firm in 2021 to focus on investments in therapeutics and enabling technologies. Aiden was previously an associate at Vida Ventures, where he worked in the firm’s LA office making investments in innovative cell and gene therapy companies. Prior to becoming an investor, Aiden worked on founding and operating biotechnology companies in San Diego California, where he is based.
Aiden traces his academic lineage to Caltech, where he earned his doctorate in the lab of Dr. Steven Mayo, a leader in the space of computational protein engineering. Aiden received his B.S. in synthetic chemistry from the University of California, Riverside.
Benjamin Kim
Partner
Ben Kim is a Partner at Playground Global where he helps identify the founders and companies that are revolutionizing engineered biology. At Playground, he has sourced and led investments into companies including Atomic AI, Infinimmune, Insamo, Outpace Bio, and Manifold Bio. Prior to Playground, Ben was a PhD graduate student and an NSF Fellow at Stanford University, where he studied Bioengineering and Biomedical Engineering.
Charles H. Lin, PhD
Principle
Charles Lin is a biotech investor at Illumina Ventures, an independently managed venture capital fund based in California. He focuses on early-stage investments in Life Science Tools, Diagnostics, AgBio, and Therapeutics, and currently serves on the boards of Pluton Biosciences and NanoCellect Biomedical. Prior to joining Illumina Ventures, Charles was VP of Business Development and Marketing at Element Biosciences, where he helped secure US$80M in Series B financing and established key strategic partnerships.
Earlier in his career, he spent over a decade at Illumina, Inc., leading R&D and corporate development initiatives, including the US$100M acquisition of Edico Genome and the proposed US$1.2B acquisition of Pacific Biosciences. Charles holds a Ph.D. in Chemistry and Chemical Biology from Harvard University and a B.Sc. in Chemistry from National Taiwan University, with postdoctoral research conducted at UC San Diego and the Howard Hughes Medical Institute.
Leighanne Oh
Vice President
Leighanne Oh, MS is a Vice President at Ascenta Capital, focusing on discovering and evaluating biotech and life sciences investments. She previously invested at Novo Holdings and Sofinnova Investments, and began her career in healthcare investment banking at Jefferies, focusing on M&A, capital raising, and advisory work for biotech and pharmaceutical companies. Trained as a biomedical engineer, she also brings operational experience from GE Healthcare, and holds an M.S. and B.S.E. in Biomedical Engineering from Duke University.
Gleb Kuznetsov
Co-Founder and CEO
Gleb Kuznetsov, PhD, is the Co-Founder and CEO of Manifold Bio, a platform biotechnology company pioneering AI-guided protein design and mega-scale in vivo screening to unlock tissue-targeted medicines. He founded Manifold Bio after completing his PhD in the Harvard Biophysics program in the lab of George Church, where he developed new approaches for protein measurement and design by combining high-throughput biology, DNA sequencing, DNA synthesis, and machine learning technologies. At Manifold, Gleb focuses on shaping strategy, building world-class teams, leading business development, and driving the company’s vision forward.
Matt Curran
Chief Executive Officer and co-founder
Matt Curran is the Chief Executive Officer and co-founder of Nanoflex Robotics, a remote surgical robotic startup based in Switzerland that aims to make life-saving procedures more accessible.
Matt has more than two decades of experience in the medical device industry. Most recently, he served as Medtronic Vice President of Cranial and Spinal Therapies for the EMEA region, where he brought the company’s first surgical robots to market.
During his time at Medtronic, he held leadership roles in different regions, including the United Kingdom, EMEA, Southeast Asia and Korea, primarily within the company’s Neurology, Spine and Pain Therapies, and Cardiac divisions. In these roles, he focused on coaching and developing multicultural teams, all while overseeing billion-dollar business units.
Matt’s passion for groundbreaking, impactful medical technologies led him to co-found Nanoflex Robotics with Christophe Chautems and Bradley Nelson in 2021, with the aim of expanding access to critical interventions through remote surgical robotics. Matt is a member of the Board of Directors at Aleva Neurotherapeutics and is actively involved in coaching programs, including supporting minority groups and early career professionals.
Matt earned an MBA from the University of Edinburgh Business School in Edinburgh, Scotland. He lives in St-George, Switzerland with his wife and two children. In his free time Matt enjoys running and kayaking.
Haim Belinson
CEO
Dr. Haim Belinson received a PhD. in neurobiology from the Tel Aviv University in Israel. Following postdoctoral training at the Department of Pediatrics, Institute for Human Genetics, UCSF, San Francisco, CA. where he studied brain development and the brain gut axis in the context of autism spectrum disorder, he joined Teva Pharmaceutical where he utilized broad neuroscience scientific expertise and lead pharmacology preclinical development of drugs for neurodegenerative diseases, neuropsychiatry and pain. At Teva, he dealt with both the scientific aspects as well as leading various stages of drug development from ideation to PhIII. Since 2018, Dr. Belinson led Bsense Bio Therapeutics as its CSO and later CEO in the development program of small molecule targeting sensory hyperexcitability from ideation to clinical candidate nomination. In 2025, Dr. Belinson joined caVos Biotherapeutics as its CEO, to lead the innovative approach of developing novel therapeutics based on naturally occurring resistance mechanisms.
Dr. Belinson has over 20 years of experience in R&D, spanning pharmaceutical R&D, target identification/validation, behavioral pharmacology and PK/PD.
Yaron Sfadyah
CEO, Coltac Therapeutics
With over a decade of global experience in managerial and business development roles, Yaron has worked across industries including medical devices, pharmaceuticals, semiconductors, and foodtech. He specializes in guiding products from R&D through international collaborations and successful commercialization across diverse markets.
Yaron lives by the motto: “We don’t stop playing because we grow old; we grow old because we stop playing” (George Bernard Shaw), later echoed by LEGO CEO Jørgen Vig Knudstorp. He believes this mindset applies equally to business—where value and technology spark engagement, but trust, creativity, and play sustain it. For Yaron, even the most complex challenges are best solved when creativity and enjoyment are part of the process.
Outside of work, Yaron is an avid (amateur) beach volleyball player and podcast host. He also helps lead a Tel Aviv-based group that organizes bi-monthly events, where speakers share personal stories of failure, fostering a culture of learning and resilience.
This blend of professional expertise and personal passions shapes Yaron’s unique perspective on both business and life.
—
Coltac Therapeutics is a biotech startup, backed by aMoon and IBF, dedicated to developing the next generation of molecular glues for targeted protein degradation.
The company is advancing three programs: two high-value oncology targets and one non-oncology, leveraging molecular glue hits discovered through its proprietary BOND+ platform.
BOND+ platform combines virtual screening with high-throughput, positive-signal bacterial validation, enabling a rapid and efficient transition to chemical optimization and mammalian cell testing.
—
Advancing Molecular Glue Discovery Through a Positive-Signal Bacterial Screening Platform |
|
Wyatt McDonnell
Co-Founder, CEO, & Chairman of the Board of Directors
Wyatt McDonnell is Co-Founder, CEO, & Chairman of the Board of Directors @ Infinimmune, a biotechnology company utilizing natural immunity to transform natural antibodies into safer and more effective drugs for complex diseases. Previously, Wyatt developed 10x Genomics’ first therapeutic antibodies and core immunology intellectual property behind three commercial products to interrogate the immune repertoire. He has co-authored 31 peer-reviewed papers in journals including Nature, Cell, and Nature Medicine, and 19 published patents in relation to immunobiology, genomics, and disease. He has been invited to speak at conferences including PEGS, the Keystone Symposia, the World Vaccine Congress, and PMWC.
Pitch Sessions
Cutting-edge startups from AI, digital health, and biotech converge to unveil the technologies redefining
AI Drug Discovery & Therapeutics
Medical Robotics & HealthTech Innovation
New Therapeutics & Drug Innovation
Organized by
RBMP
IBMI
Everbright Biofund
Supported by
MEDTEX Countdown
Dec 3, 2025 · 10:00 – 17:00
2025 Medtex
Past Events
Regulations
© EverRise Biomedical Co. Ltd. All rights reserved.